Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Amortizatization of Intangibles (2016 - 2025)

Historic Amortizatization of Intangibles for Arrowhead Pharmaceuticals (ARWR) over the last 15 years, with Q4 2025 value amounting to $1.2 million.

  • Arrowhead Pharmaceuticals' Amortizatization of Intangibles fell 7869.92% to $1.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.3 million, marking a year-over-year decrease of 8397.63%. This contributed to the annual value of $5.8 million for FY2025, which is 7845.25% up from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Amortizatization of Intangibles of $1.2 million as of Q4 2025, which was down 7869.92% from $1.2 million recorded in Q3 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Amortizatization of Intangibles ranged from a high of $11.1 million in Q3 2024 and a low of -$7.0 million during Q2 2024
  • Over the past 5 years, Arrowhead Pharmaceuticals' median Amortizatization of Intangibles value was $165500.0 (recorded in 2021), while the average stood at $439350.0.
  • Per our database at Business Quant, Arrowhead Pharmaceuticals' Amortizatization of Intangibles plummeted by 340196.08% in 2022 and then skyrocketed by 102765.96% in 2024.
  • Quarter analysis of 5 years shows Arrowhead Pharmaceuticals' Amortizatization of Intangibles stood at $280000.0 in 2021, then plummeted by 346.43% to -$690000.0 in 2022, then surged by 221.01% to $835000.0 in 2023, then skyrocketed by 583.11% to $5.7 million in 2024, then tumbled by 78.7% to $1.2 million in 2025.
  • Its last three reported values are $1.2 million in Q4 2025, $1.2 million for Q3 2025, and $1.8 million during Q2 2025.